CN1330658A - 利用韦林－α－干扰素联合疗法根除慢性丙型肝炎感染患者可检测的HCV－RNA - Google Patents

利用韦林－α－干扰素联合疗法根除慢性丙型肝炎感染患者可检测的HCV－RNA Download PDF

Info

Publication number
CN1330658A
CN1330658A CN99814344A CN99814344A CN1330658A CN 1330658 A CN1330658 A CN 1330658A CN 99814344 A CN99814344 A CN 99814344A CN 99814344 A CN99814344 A CN 99814344A CN 1330658 A CN1330658 A CN 1330658A
Authority
CN
China
Prior art keywords
alkyl
formula
compound
interferon
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99814344A
Other languages
English (en)
Chinese (zh)
Inventor
A·K·甘古利
J·麦科尔米克
R·G·罗维
F·本尼特
A·K·萨克塞纳
V·M·吉里雅瓦拉班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1330658A publication Critical patent/CN1330658A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN99814344A 1998-10-16 1999-10-14 利用韦林－α－干扰素联合疗法根除慢性丙型肝炎感染患者可检测的HCV－RNA Pending CN1330658A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/174059 1998-10-16
US09/348534 1999-07-07
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
CN1330658A true CN1330658A (zh) 2002-01-09

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99814344A Pending CN1330658A (zh) 1998-10-16 1999-10-14 利用韦林－α－干扰素联合疗法根除慢性丙型肝炎感染患者可检测的HCV－RNA

Country Status (20)

Country Link
EP (1) EP1121369B1 (https=)
JP (1) JP2002527522A (https=)
CN (1) CN1330658A (https=)
AT (1) ATE284408T1 (https=)
AU (1) AU762395B2 (https=)
BR (1) BR9915546A (https=)
CA (1) CA2346447C (https=)
CZ (1) CZ20011130A3 (https=)
DE (1) DE69922529T2 (https=)
ES (1) ES2229820T3 (https=)
HU (1) HUP0200447A2 (https=)
ID (1) ID29187A (https=)
IL (1) IL142423A0 (https=)
NO (1) NO20011789L (https=)
NZ (1) NZ510811A (https=)
PL (1) PL347268A1 (https=)
RU (1) RU2001113268A (https=)
SK (1) SK4742001A3 (https=)
TR (1) TR200101085T2 (https=)
WO (1) WO2000023454A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513055A (zh) * 2017-08-11 2017-12-26 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
JPWO2009028575A1 (ja) 2007-08-27 2010-12-02 国立大学法人名古屋大学 血液凝固第ｖｉｉ因子プロモーターの活性化剤及びその利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド ポリヌクレオチド構築物
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US20240325419A1 (en) 2022-05-05 2024-10-03 Abdula Kurkayev Pharmaceutical composition for restoring physiological processes and cells of organism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
JP2001503767A (ja) * 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513055A (zh) * 2017-08-11 2017-12-26 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物

Also Published As

Publication number Publication date
AU762395B2 (en) 2003-06-26
ID29187A (id) 2001-08-09
CZ20011130A3 (cs) 2001-08-15
IL142423A0 (en) 2002-03-10
ES2229820T3 (es) 2005-04-16
JP2002527522A (ja) 2002-08-27
SK4742001A3 (en) 2001-11-06
NO20011789L (no) 2001-06-11
CA2346447A1 (en) 2000-04-27
DE69922529T2 (de) 2005-12-15
TR200101085T2 (tr) 2001-08-21
NZ510811A (en) 2003-06-30
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
AU1197500A (en) 2000-05-08
WO2000023454A1 (en) 2000-04-27
RU2001113268A (ru) 2003-09-27
ATE284408T1 (de) 2004-12-15
EP1121369A1 (en) 2001-08-08
BR9915546A (pt) 2001-08-14
CA2346447C (en) 2006-01-31
PL347268A1 (en) 2002-03-25
NO20011789D0 (no) 2001-04-09
EP1121369B1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
CN1330658A (zh) 利用韦林－α－干扰素联合疗法根除慢性丙型肝炎感染患者可检测的HCV－RNA
JP2023526179A (ja) ヌクレオシド類似体またはヌクレオシド類似体を含有する併用製剤の抗ウイルスにおける使用
US20020055473A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CN1195526C (zh) 含对映体纯β－D－二氧戊环核苷的药物产品
CN1036196C (zh) 1，3-氧硫环戊烷核苷类似物的制备方法
US20200276198A1 (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon
CN1052010C (zh) 苯并咪唑衍生物及其制备方法和用途以及含该衍生物的药物制剂
US6277830B1 (en) 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6525033B1 (en) Nucleosides with anti-hepatitis B virus activity
CN1427722A (zh) 用核苷类似物治疗或预防黄病毒感染的方法
WO2018087345A1 (en) COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
CN1541105A (zh) 用维生素b12和干扰素联合治疗病毒性、增殖性和炎性疾病的方法
CN1482914A (zh) 丙型肝炎治疗剂
US6673775B2 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CN1100303A (zh) 作为抗乙肝(hbv)及抗hiv药物的l-2′，3′，-二去氧核苷类似物
CN1349408A (zh) 聚乙二醇化干扰素α－CCR5拮抗剂联合HIV疗法
US20120220520A1 (en) Bioavailable combinations for hcv treatment
JP2014237678A (ja) Ｈｃｖを治療するためのリトナビルの組成物及び使用方法
CN105348345A (zh) 一种含有硫普罗宁结构的前药、其制备方法、药物组合物及其用途
CN1089239C (zh) 治疗或预防动物炎症和组织损害用的嘧啶核苷酸前体
CN1368887A (zh) 与PEG－IFN－α结合的霉酚酸酯Mofetil
CN1253504A (zh) 细胞因子相关的疾病治疗法
CN1178660C (zh) 抗病毒药物组合
CN1244799A (zh) L－β－二氧戊环尿苷类似物和治疗和预防病毒感染的方法
CN1416351A (zh) Hiv免疫辅助治疗

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned